The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. Chrysavgis L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al. J Gastroenterol Hepatol 2021;36:893-909.

Read + Share

Amedeo Smart

Independent Medical Education

Chrysavgis L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:893-909.
PMID: 33439540